Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
published in: Clinical Colorectal Cancer
date of publication: 2016-09-07
language: English
main subject: biomarker, colorectal cancer, cetuximab, metastatic colon cancer
Cites articles
There is nothing here
Article - wd:Q39250247